These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 21990269)

  • 21. Synthesis and evaluation of tacrine-E2020 hybrids as acetylcholinesterase inhibitors for the treatment of Alzheimer's disease.
    Shao D; Zou C; Luo C; Tang X; Li Y
    Bioorg Med Chem Lett; 2004 Sep; 14(18):4639-42. PubMed ID: 15324879
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potent anticholinesterasic and neuroprotective pyranotacrines as inhibitors of beta-amyloid aggregation, oxidative stress and tau-phosphorylation for Alzheimer's disease.
    García-Font N; Hayour H; Belfaitah A; Pedraz J; Moraleda I; Iriepa I; Bouraiou A; Chioua M; Marco-Contelles J; Oset-Gasque MJ
    Eur J Med Chem; 2016 Aug; 118():178-92. PubMed ID: 27128182
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multi-target-directed ligands for treating Alzheimer's disease: Butyrylcholinesterase inhibitors displaying antioxidant and neuroprotective activities.
    Knez D; Coquelle N; Pišlar A; Žakelj S; Jukič M; Sova M; Mravljak J; Nachon F; Brazzolotto X; Kos J; Colletier JP; Gobec S
    Eur J Med Chem; 2018 Aug; 156():598-617. PubMed ID: 30031971
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design, synthesis and evaluation of novel tacrine-multialkoxybenzene hybrids as dual inhibitors for cholinesterases and amyloid beta aggregation.
    Luo W; Li YP; He Y; Huang SL; Tan JH; Ou TM; Li D; Gu LQ; Huang ZS
    Bioorg Med Chem; 2011 Jan; 19(2):763-70. PubMed ID: 21211982
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tacrines as Therapeutic Agents for Alzheimer's Disease. IV. The Tacripyrines and Related Annulated Tacrines.
    Bartolini M; Marco-Contelles J
    Chem Rec; 2019 May; 19(5):927-937. PubMed ID: 30489012
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis and Biological Assessment of Racemic Benzochromenopyrimidinimines as Antioxidant, Cholinesterase, and Aβ1-42 Aggregation Inhibitors for Alzheimer's Disease Therapy.
    Dgachi Y; Ismaili L; Knez D; Benchekroun M; Martin H; Szałaj N; Wehle S; Bautista-Aguilera OM; Luzet V; Bonnet A; Malawska B; Gobec S; Chioua M; Decker M; Chabchoub F; Marco-Contelles J
    ChemMedChem; 2016 Jun; 11(12):1318-27. PubMed ID: 26804623
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The bivalent ligand approach as a tool for improving the in vitro anti-Alzheimer multitarget profile of dimebon.
    Rosini M; Simoni E; Bartolini M; Soriano E; Marco-Contelles J; Andrisano V; Monti B; Windisch M; Hutter-Paier B; McClymont DW; Mellor IR; Bolognesi ML
    ChemMedChem; 2013 Aug; 8(8):1276-81. PubMed ID: 23824986
    [No Abstract]   [Full Text] [Related]  

  • 28. Polyoxometalates as inhibitors of the aggregation of amyloid β peptides associated with Alzheimer's disease.
    Geng J; Li M; Ren J; Wang E; Qu X
    Angew Chem Int Ed Engl; 2011 Apr; 50(18):4184-8. PubMed ID: 21433228
    [No Abstract]   [Full Text] [Related]  

  • 29. Biological Evaluation of 8-Hydroxyquinolines as Multi-Target Directed Ligands for Treating Alzheimer's Disease.
    Knez D; Sosič I; Pišlar A; Mitrović A; Jukič M; Kos J; Gobec S
    Curr Alzheimer Res; 2019; 16(9):801-814. PubMed ID: 31660830
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chalcone-based carbamates for Alzheimer's disease treatment.
    Rampa A; Montanari S; Pruccoli L; Bartolini M; Falchi F; Feoli A; Cavalli A; Belluti F; Gobbi S; Tarozzi A; Bisi A
    Future Med Chem; 2017 May; 9(8):749-764. PubMed ID: 28498775
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Donepezil-based multi-functional cholinesterase inhibitors for treatment of Alzheimer's disease.
    Li Q; He S; Chen Y; Feng F; Qu W; Sun H
    Eur J Med Chem; 2018 Oct; 158():463-477. PubMed ID: 30243151
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel class of quinone-bearing polyamines as multi-target-directed ligands to combat Alzheimer's disease.
    Bolognesi ML; Banzi R; Bartolini M; Cavalli A; Tarozzi A; Andrisano V; Minarini A; Rosini M; Tumiatti V; Bergamini C; Fato R; Lenaz G; Hrelia P; Cattaneo A; Recanatini M; Melchiorre C
    J Med Chem; 2007 Oct; 50(20):4882-97. PubMed ID: 17850125
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis, biological assessment, and molecular modeling of racemic 7-aryl-9,10,11,12-tetrahydro-7H-benzo[7,8]chromeno[2,3-b]quinolin-8-amines as potential drugs for the treatment of Alzheimer's disease.
    Maalej E; Chabchoub F; Oset-Gasque MJ; Esquivias-Pérez M; González MP; Monjas L; Pérez C; de los Ríos C; Rodríguez-Franco MI; Iriepa I; Moraleda I; Chioua M; Romero A; Marco-Contelles J; Samadi A
    Eur J Med Chem; 2012 Aug; 54():750-63. PubMed ID: 22795665
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The new approach in development of anti-Alzheimer's disease drugs via the cholinergic hypothesis.
    Sugimoto H
    Chem Biol Interact; 2008 Sep; 175(1-3):204-8. PubMed ID: 18577377
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Advances toward multifunctional cholinesterase and β-amyloid aggregation inhibitors.
    Panek D; Wichur T; Godyń J; Pasieka A; Malawska B
    Future Med Chem; 2017 Oct; 9(15):1835-1854. PubMed ID: 28925729
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Syntheses and characterization of novel oxoisoaporphine derivatives as dual inhibitors for cholinesterases and amyloid beta aggregation.
    Li YP; Ning FX; Yang MB; Li YC; Nie MH; Ou TM; Tan JH; Huang SL; Li D; Gu LQ; Huang ZS
    Eur J Med Chem; 2011 May; 46(5):1572-81. PubMed ID: 21367493
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A novel anti-Alzheimer's disease drug, ladostigil neuroprotective, multimodal brain-selective monoamine oxidase and cholinesterase inhibitor.
    Weinreb O; Amit T; Bar-Am O; Youdim MB
    Int Rev Neurobiol; 2011; 100():191-215. PubMed ID: 21971009
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of acetylcholinesterase, beta-amyloid aggregation, and NMDA receptors in Alzheimer's disease: a promising direction for the multi-target-directed ligands gold rush.
    Rosini M; Simoni E; Bartolini M; Cavalli A; Ceccarini L; Pascu N; McClymont DW; Tarozzi A; Bolognesi ML; Minarini A; Tumiatti V; Andrisano V; Mellor IR; Melchiorre C
    J Med Chem; 2008 Aug; 51(15):4381-4. PubMed ID: 18605718
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neuroprotective effects of multifaceted hybrid agents targeting MAO, cholinesterase, iron and β-amyloid in ageing and Alzheimer's disease.
    Weinreb O; Amit T; Bar-Am O; Youdim MB
    Br J Pharmacol; 2016 Jul; 173(13):2080-94. PubMed ID: 26332830
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-cholinesterase hybrids as multi-target-directed ligands against Alzheimer's disease (1998-2018).
    Mishra P; Kumar A; Panda G
    Bioorg Med Chem; 2019 Mar; 27(6):895-930. PubMed ID: 30744931
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.